Elderly patients with advanced colorectal cancer: which therapy is the safest?

Bibliography

• POPESCU RA, NORMAN A, ROSS PJ et al.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Chu. Oncol (1999) 17:2412–2418.
   PubMed Web of Science ®Google Scholar
• BALDUCCI L, BEGHE C: The application of the principles of geriatrics to the management of the older person with cancer. Crk Rev Oncol Hematol (2000) 35:147–154.
   PubMed Web of Science ®Google Scholar
• •Principles of general management of elderly patients.
   Google Scholar
• MILLNER MD, PARADIS CE HOUCK PR et al: Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. (1992) 41:237–248.
   PubMed Web of Science ®Google Scholar
• REPETTO L, FRATINO L, AUDISIO RAet al.: Comprehensive geriatric assessment adds information to Eastern cooperative cncology group performance status in elderly cancer patients: an Italian group for geriatric oncology study./. Clin. Oncol (2002) 20:494–502.
   Google Scholar
• •Validation of comprehensive geriatric assessment in elderly patients.
   Google Scholar
• KOHNE CH, GROTHEY A, BOKEMEYER C, BONTKE N, AAPRO M: Chemotherapy in elderly patients with colorectal cancer. Ann. Oncol (2001) 12:435–442.
   PubMed Web of Science ®Google Scholar
• •Exhaustive review of chemotherapy in elderly patients.
   Google Scholar
• SARGENT DJ, GOLDBERG RM, JACOBSON SD et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl. J. Med. (2001) 345:1091–1097.
   PubMed Web of Science ®Google Scholar
• DIASIO RB, HARRIS BE: Clinical pharmacology of 5-fluorouracil. Chu. Pharmacokinet. (1989) 16:215–237.
   PubMed Web of Science ®Google Scholar
• FLEMING FG, SCHILSKY RL: Phase I and pharmacological study of 5-fluorouracil in patients with hepatic and renal dysfunction. Proc. Am. Assoc. Cancer Res. (1993) 34:396.
   Google Scholar
• MILANO G, ETIENNE MC, CASSUTO-VIGUIER E et al: Influence of sex and age on fluorouracil clearance. J. Clin. Oncol (1992) 10:1171–1175.
   PubMed Web of Science ®Google Scholar
• BERETTA G, BOLLINA R, COZZI C et al.: Should we consider the weekly chemotherapy with fluorouracil + racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proc. Am. Soc. Chu. Oncol (1997) 16:259a.
   Google Scholar
• DANIELE B, ROSATI G, TAMBARO R et al: First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. I Clin. Castroenterol (2003) 36:228–233.
   PubMed Web of Science ®Google Scholar
• MATTIOLI R, LIPPE P, RECCHIA F et al: Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res. (2001) 21:489–492.
   PubMed Web of Science ®Google Scholar
• FOLPRECHT G, CUNNINGHAM D, ROSS P et al: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol (2004) 15:1330–1338.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, ZALCBERG J, RATH U et al: Final results of a randomised trial comparing `Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol (1996) 7:961–965.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Drug-company decision to end cancer trial. Lancet (1999) 354:1045.
   PubMed Web of Science ®Google Scholar
• KOHNE CH, THUSS-PATIENCE P, FRIEDRICH M et al.: Raltitrexed (Tomudex): An alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. BE J. Cancer (1998) 77:973–977.
   Web of Science ®Google Scholar
• MEL JR, FELIU J, CAMPS C et al: Tomudex (Raltitrexed) in elderly patients with advanced colorectal cancer: an effective palliative treatment. Proc. Am. Soc. Clin. Oncol. (2000) 19:257a.
   Google Scholar
• FACCHINI T, GENET D, BERDAH JF et al.: Raltitrexed (Tomudex) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: final analysis of a multicentre study. Proc. Am. Soc. Clin. Oncol. (2000) 19:298a.
   Google Scholar
• RUSTUM YM: Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology (199 7) 54\(Suppl. 11):7–11.
   Google Scholar
• HOFF PM, PAZDUR R, BENNER SE et al.: UFT and leucovorin : a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs (1998) 9:479–490.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, DOUILLARD JY, SKILLINGS JR et al.: Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTm in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:263a.
   Google Scholar
• CARMICHAEL J, POPIELA T, RADSTONE D et al.: Randomized comparative study of ORZEL (oral uracil/ tegafur (UFT)TM) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU plus LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:264a.
   Google Scholar
• DIAZ-RUBIO E, SASTRE J, ABAD A et al.: UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (1999) 13:35–40.
   PubMed Web of Science ®Google Scholar
• FELIU J, GONZALEZ BARON M, ESPINOSA E et al.: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer (1997) 79:1884–1889.
   Google Scholar
• POPA EC, LUO W, HOCHSTER H et al: A phase II study of orzel (UFT-Fleucovorin) in elderly75 years old) patients withcolorectal cancer: results of ECOG 1299. Proc. Am. Soc. Clin Oncol. (2005) 24:273s.
   Google Scholar
• TWELVES C, GLYNNE-JONES R, CASSIDY J et al: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. (1999) 5:1696–1702.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al.: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. I Clin. Oncol. (2000) 18:1337–1345.
   PubMed Web of Science ®Google Scholar
• HOFF PM, ANSARI R, BATIST G et al: Comparison of oral capecitabine (Xeloda) versus intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Oncol. (2001) 19:2282–2292.
   Google Scholar
• TWELVES C, HARPER P, VAN CUTSEM E et al: A phase III trial (S014796) of XelodaTm (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:263a.
   Google Scholar
• CRIPPS MC, VINCENT M, JONKER D et al: Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:265s.
   Google Scholar
• DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041–1047.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl. J. Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, ZINNER R, ROTHENBERG M et al: Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:260a.
   Google Scholar
• SCHAAF LJ, ICHHPURANI N, ELFRING GL et al.: Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1998) 16:202a.
   Google Scholar
• STEWART G, CHAU I, NORMAN AR et al: Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 23:276.
   Google Scholar
• ROTHENBERG ML, COX JV, DEVORE RF et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 85:786–795.
   PubMed Web of Science ®Google Scholar
• BOLLINA R, TONIOLO D, BELLONI P et al.: Oxaliplatin and irinotecan: phase I/II study in 5FU refractory advanced colorectal cancer elderly patients, a second line treatment. Proc. Am. Soc. Clin. (2001) 20:407a.
   Google Scholar
• SASTRE J, MARCUELLO E, MASUTTI B et al.: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study. J. Clin. Oncol. (2005) 23:3545–3551.
   PubMed Web of Science ®Google Scholar
• •Phase II study with irinotecan In combination therapy.
   Google Scholar
• BOTTO HG, BOTTO ME: Combination of irinotecan and 5-fluorouracil, leucovorin in first and second line treatment in elderly patients with metastatic cob-rectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:306s.
   PubMed Web of Science ®Google Scholar
• FIORENTINI G, DENTICO P, CANTORE M et al: Capecitabine plus irinotecan as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: Feasibility and safety results from a phase II study. Proc. Am. Soc. Clin. Oncol. (2005) 24:289s.
   Web of Science ®Google Scholar
• RAYMOND E, FAIVRE S, WOYNAROWSKI JM, CHANEY SG: Oxaliplatin: mechanism of action and antineoplastic activity. Sem:M. Oncol. (1998) 25\(Suppl. 5):4–12.
   Google Scholar
• DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer.' Clin. Oncol. (2000) 18:2938–2947.
   Web of Science ®Google Scholar
• BERRETTA A, BUONADONNA A, RUPOLO M et al.: Comparison between elderly and non-elderly patients of efficacy and tolerability of FOLFOX2 schedule in advanced colorectal cancer. Proc. Am. Soc. Oncol. (2001) 20:111b.
   Google Scholar
• COMELLA P, GAMBARDELLA A, FARRIS A et al: A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma. Southern Italy Cooperative Oncology Group trial 0108. Grit. Rev Oncol. Hematol. (2005) 53:133–139.
   Google Scholar
• TWELVES C, BUTTS C, CASSIDY J et al.: XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): Post-hoc analysis of a large phase II study. Proc. Am. Soc. Clin. Oncol. (2004) 23:259.
   Google Scholar
• LOPEZ-GOMEZ L, ESCUDERO P, YUBERO A et al.: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/ metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2004) 23:292.
   Google Scholar
• SALUD A, ESCUDERO P, FEUD J et al: XELOX (capecitabine and oxaliplatin) as Pt line treatment for elderly patients with advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:276s.
   Google Scholar
• COMANDONE A, POCHETTINO P, BERGNOLO P et Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:291s.
   Google Scholar
• ROSATI G, CORDIO S, TUCCI A et al: Phase II trial of oxaliplatin and tegafur/ uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology (2005) 69:122–129.
   PubMed Web of Science ®Google Scholar
• •Phase II trial with oxaliplatin In combination therapy.
   Google Scholar
• MASSACESI C, LIPPE P, RECCHIA F et al: Bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:275s.
   Web of Science ®Google Scholar
• OH DY, KIM YJ, HAN SW et al: Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:300s.
   Google Scholar